 |
|
|
| |
TARGET3D: glecaprevir-pibrentasvir for four weeks among people with recent HCV infection
|
| |
| |
CROI 2023 Feb 20-23
Marianne Martinello1,2, Sanjay Bhagani3, David Shaw4, Chloe Orkin5, Graham Cooke6, Edward Gane7, Margaret Hellard8,9, Andrew Ustianowski10, Ranjababu Kulasegaram11, Catherine Stedman12, Elise Tu1, Jason
Grebely1, Gregory J Dore1,13, Mark Nelson14*, Gail V Matthews1,13* (*joint senior author)
1. Kirby Institute, UNSW Sydney, Sydney, Australia; 2. Department of Infectious Diseases, Prince of Wales Hospital, Sydney, Australia; 3. Department of Infectious Diseases/HIV Medicine, Royal Free Hospital, London, UK; 4. Department of Infectious Diseases, Royal Adelaide Hospital, Adelaide, Australia; 5. Queen Mary University of London, London, UK; 6. Department of Infectious Diseases, Imperial College NHS Trust, St Mary's Hospital, London, UK; 7. New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 8. ; 8. Burnet Institute, Melbourne, Australia; 9. The Alfred Hospital, Melbourne,
Australia; 10. North Manchester General Hospital, Manchester, UK; 11. Guy's and St. Thomas' Hospital, London, UK; 12. Christchurch Hospital, Christchurch, New Zealand; 13. Department of Infectious Diseases, St Vincent's Hospital, Sydney, Australia; 14. Chelsea and Westminster Hospital, London, UK
Disclosures: The Kirby Institute is funded by the Australian Government Department of Health and Ageing. Research reported in this publication was supported by Abbvie as an investigator-initiated study. None of the authors has commercial relationships that might pose a conflict of interest in connection with this presentation.
|
| |
|
|
|
|
|
